SLNSW-Clinical development of galunisertib (LY2157299 m...-TN_cdi_doaj_primary_oai_doaj_org_article_7528a401427b41a9904e8212050c3fe0

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Full title: Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Author/creator: Herbertz, Stephan, Sawyer, J Scott, Stauber, Anja J, Gueorguieva, Ivelina, Driscoll, Kyla E, Estrem, Shawn T, Cleverly, Ann L, Desaiah, Durisala, Guba, Susan C, Benhadji, Karim A, Slapak, Christopher A, Lahn, Michael M.

Call Numbers:

Record Identifier: TN_cdi_doaj_primary_oai_doaj_org_article_7528a401427b41a9904e8212050c3fe0

Language: English

Formats: Articles

Publishers: New Zealand: Dove Medical Press Limited

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7528a401427b41a9904e8212050c3fe0

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

    Record identifier

    TN_cdi_doaj_primary_oai_doaj_org_article_7528a401427b41a9904e8212050c3fe0

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7528a401427b41a9904e8212050c3fe0

    Share

    Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7528a401427b41a9904e8212050c3fe0

    Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

    Full title

    Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

    Author / Creator

    Herbertz, Stephan ; Sawyer, J Scott ; Stauber, Anja J ; Gueorguieva, Ivelina ; Driscoll, Kyla E ; Estrem, Shawn T ; Cleverly, Ann L ; Desaiah, Durisala ; Guba, Susan C ; Benhadji, Karim A ; Slapak, Christopher A ; Lahn, Michael M

    Publisher

    New Zealand: Dove Medical Press Limited

    Journal title

    Drug design, development and therapy, 2015, Vol.9 (default), p.4479-4499

    Record Identifier

    TN_cdi_doaj_primary_oai_doaj_org_article_7528a401427b41a9904e8212050c3fe0

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Administration, Oral ALK5 Angiogenesis Animal models Anticancer properties Antimitotic agents Antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antisense oligonucleotides Antitumor activity Biological activity Breast cancer cancer Cancer therapies Cellular signal transduction Clinical trials Colon Cytokines Dosage Drug Administration Schedule Drug Discovery Drug resistance Drug therapy Fibroblasts galunisertib Glioblastoma Growth factors Health aspects Heart Diseases - chemically induced Hepatocellular carcinoma Immunosurveillance Inhibitors Kinases Laboratories Ligands Lung carcinoma LY2157299 Melanoma Metastases Metastasis Molecular Structure Molecular Targeted Therapy Monoclonal antibodies Neoplasms - drug therapy Neoplasms - enzymology Neoplasms - pathology Oligonucleotides Pancreatic cancer Pancreatic carcinoma Patients Pharmacodynamics Pharmacology Phosphorylation Physiology Prostate cancer Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - chemistry Protein Kinase Inhibitors - pharmacokinetics Protein Kinase Inhibitors - therapeutic use Protein-Serine-Threonine Kinases - antagonists & inhibitors Protein-Serine-Threonine Kinases - metabolism Proteins Pyrazoles - administration & dosage Pyrazoles - adverse effects Pyrazoles - chemistry Pyrazoles - pharmacokinetics Pyrazoles - therapeutic use Quinolines - administration & dosage Quinolines - adverse effects Quinolines - chemistry Quinolines - pharmacokinetics Quinolines - therapeutic use Receptors, Transforming Growth Factor beta - antagonists & inhibitors Receptors, Transforming Growth Factor beta - metabolism Review Signal transduction Signal Transduction - drug effects Signaling Smad2 protein Smad2 Protein - metabolism Targeted cancer therapy Testing TGF-β TGF-βRI kinase inhibitor Toxicity Transcription factors Transforming growth factor-b Transforming growth factors Treatment Outcome Tumorigenesis Tumors Vaccines Xenograft Model Antitumor Assays

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_doaj_primary_oai_doaj_org_article_7528a401427b41a9904e8212050c3fe0

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7528a401427b41a9904e8212050c3fe0

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections